Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Kamban Hirasen"'
Autor:
Bevis Phiri, Alana T. Brennan, Lloyd Mulenga, Timothy Tcherini, Hilda Shakwelele, Prudence Haimbe, Andrews Gunda, Bilaal Wilson Matola, Rose Nyirenda, Sydney Rosen, Kamban Hirasen, Amy Huber
Publikováno v:
Gates Open Research, Vol 7 (2023)
Background: Since 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries have incorporated a SDI option into na
Externí odkaz:
https://doaj.org/article/daf1e723f4924f43a564008f8d06e5ab
Autor:
Denise Evans, Kamban Hirasen, Rebecca Berhanu, Given Malete, Prudence Ive, David Spencer, Sharlaa Badal-Faesen, Ian M. Sanne, Matthew P. Fox
Publikováno v:
AIDS Research and Therapy, Vol 15, Iss 1, Pp 1-12 (2018)
Abstract Background While efficacy data exist, there are limited data on the outcomes of patients on third-line antiretroviral therapy (ART) in sub-Saharan Africa in actual practice. Being able to identify predictors of switch to third-line ART will
Externí odkaz:
https://doaj.org/article/6a7a2ff2cee94eae8418f7284dbf4351
Autor:
Craig van Rensburg, Rebecca Berhanu, Kamban Hirasen, Denise Evans, Sydney Rosen, Lawrence Long
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0217820 (2019)
BackgroundDrug resistant-tuberculosis is a growing burden on the South African health care budget. In response the National Department of Health implemented two important strategies in 2011; universal access to drug-sensitivity testing for rifampicin
Externí odkaz:
https://doaj.org/article/aef12d0a613a47349046f80c7c981081
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205463 (2018)
INTRODUCTION:Treatment success rates of rifampicin resistant (RR)/multi-drug resistant (MDR) tuberculosis (TB) in South Africa range from 43-48%, falling short of the World Health Organization's target of ≥75%. We present rates and assess predictor
Externí odkaz:
https://doaj.org/article/a77b5a62888340ea9fdadd28ffe6d0e5
Autor:
Kate Shearer, Denise Evans, Barbara Xhosa, Kamban Hirasen, Craig Bracken, Kay Mahomed, Lawrence Long, Matthew P Fox
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203797 (2018)
BACKGROUND:Depression is a leading cause of disability and may be associated with decreased adherence to ART. We sought to describe the prevalence of depressive symptoms and outcomes one year after screening among patients receiving ART at a large HI
Externí odkaz:
https://doaj.org/article/925ac92b34ec4b01a54a32112b0efbbd
Autor:
Rebecca Berhanu, Kathryn Schnippel, Erika Mohr, Kamban Hirasen, Denise Evans, Sydney Rosen, Ian Sanne
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0164974 (2016)
We describe baseline characteristics, time to treatment initiation and interim patient outcomes at a decentralized, outpatient treatment site for rifampicin-resistant TB (RR-TB).Prospective observational cohort study of RR-TB patients from March 2013
Externí odkaz:
https://doaj.org/article/070fb8d598f542679486226065a3c69c
Autor:
Amy Huber, Kamban Hirasen, Alana T Brennan, Bevis Phiri, Timothy Tchereni, Lloyd Mulenga, Prudence Haimbe, Hilda Shakwelele, Rose Nyirenda, Bilaal Wilson Matola, Andrews Gunda, Sydney Rosen
IntroductionSince 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries in sub-Saharan Africa have incorporate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d2b990c08e6c062f0c8da0bbafeaacf
https://doi.org/10.1101/2022.11.28.22282854
https://doi.org/10.1101/2022.11.28.22282854
Autor:
Amy Huber, Kamban Hirasen, Alana T. Brennan, Bevis Phiri, Timothy Tcherini, Lloyd Mulenga, Prudence Haimbe, Hilda Shakwelele, Rose Nyirenda, Bilaal Wilson Matola, Andrews Gunda, Sydney Rosen
Publikováno v:
Gates Open Research. 7:42
Background: Since 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries have incorporated a SDI option into na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba5f54533149b0926daad446cdd50363
https://doi.org/10.12688/gatesopenres.14424.2
https://doi.org/10.12688/gatesopenres.14424.2
Publikováno v:
Therapeutics and Clinical Risk Management. 16:169-180
Introduction Officially rolled out on 01 September 2016, South Africa's Universal Test and Treat (UTT) policy calls for first-line antiretroviral treatment (ART) initiation among all known HIV-positive patients, irrespective of CD4 cell count. We eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c62eb54abd6afbc6692772e348fc28ff
https://doi.org/10.2147/tcrm.s227290
https://doi.org/10.2147/tcrm.s227290
Autor:
Sello Mashamaite, Matthew P. Fox, Kamban Hirasen, Nelly Jinga, Denise Evans, Julia Turner, Rita Grabe, Lawrence Long
Publikováno v:
Patient preference and adherence
Kamban Hirasen,1,* Denise Evans,1,* Nelly Jinga,1 Rita Grabe,2 Julia Turner,2 Sello Mashamaite,2 Lawrence C Long,1,3 Matthew P Fox1,3,4 1Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8880835e976257d21de69ecf62c325cc
https://doi.org/10.2147/ppa.s210404
https://doi.org/10.2147/ppa.s210404